• Subscribe
  • Log In
  • Corporate
  • DONATE
  • LinkedIn
  • X
The Global Health Report
  • Policy
  • Companies
  • Research
  • People
  • AI
Latest news
  • May 1, 2026 | Valneva shores up balance sheet after mixed trial results
  • April 30, 2026 | Novartis’ malaria drug for newborns cleared by WHO
  • April 29, 2026 | Outbreaks top AI concern – priority-setting report
  • March 9, 2026 | Real-time data on global dengue outbreaks
  • November 5, 2025 | Davos brain health plan hopes to unlock Africa funds
Valneva has issued almost 16 million new shares. Image courtesy of Valneva

Companies May 1, 2026

Valneva shores up balance sheet after mixed trial results

Vaccine specialist Valneva has sold new shares worth €84 million as it moves to strengthen its balance sheet in the wake of mixed results for…

Read More
Coartem Baby was developed by Novartis with scientific and financial support from the Medicines for Malaria Venture. Image from flickr, courtesy of World Bank

Medicines

Novartis’ malaria drug for newborns cleared by WHO

Monitoring and preparing for disease outbreaks should be the top consideration for AI developers in global health, the first-ever global priority-setting report has concluded. Image Wikimedia Commons, courtesey of IICD

AI

Outbreaks top AI concern – priority-setting report

The Global Dengue Observatory provides an estimate of the current global dengue situation. Image courtesy of Global Dengue Observatory

Disease

Real-time data on global dengue outbreaks

Wider use of existing brain health treatments could add $6.2 trillion to global economic output every year from 2050.

Policy

Davos brain health plan hopes to unlock Africa funds

Strong performance in its long-acting HIV preventable has helped GlaxoSmithKline to raise its profit forecasts

Companies

GSK’s Q3 results buoyed by long-acting HIV jab

South Africa's Minister of Health Aaron Motsoaledi said the country plans to make Gilead’s twice-yearly HIV preventative lenacapavir into a 'public good'

Policy

South Africa to make Gilead’s lenacapavir a ‘public good’

Sanofi has created a brand of affordable drugs for NCD patients called Impact, tackling cardiovascular diseases, cancers, and diabetes

Companies

Sanofi Global Health Unit says 1 mln reached since 2021

At the Seventh Replenishment summit in 2022, the US committed $6 billion, out of a record $15 billion raised.

Companies

Viiv/GSK pledge $8 mln ahead of Global Fund summit

Colorized scanning electron micrograph showing carbapenem-resistant Klebsiella pneumoniae. Image Wikimedia Commons

Medicines October 20, 2025

‘Especially concerning’ AMR data for Africa – WHO

Over 70 per cent of bloodstream infections in Africa with two common bacteria are now resistant to mainstay antibiotics, according to the latest WHO report….

1 2 3 »

Most popular

  • The US has so far funded a third of the cost of fighting mpox.US aid suspension threatens mpox fight
  • Uganda has started the world’s biggest malaria vaccination campaign.Uganda launches largest-ever malaria vaccine drive
  • African countries are at risk of missing out on flu jabs in the case of a pandemic, according to the latest study from the WHO.Africa could miss out in a pandemic – study
  • The world is off track to meet the health-related SDGs, amid a darkening geopolitical outlook for health spending.World off-track to meet health SDGs – WHO
  • South Africa's Minister of Health Aaron Motsoaledi said the country plans to make Gilead’s twice-yearly HIV preventative lenacapavir into a 'public good'South Africa to make Gilead’s lenacapavir a ‘public good’
  • Privacy Policy
  • Account
  • About us

Copyright 2026 | MH Newsdesk by MH Themes

Receive our fortnightly briefing on AI in global health

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.